Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 309


Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F.

J Nucl Med. 2010 Apr;51(4):624-31. doi: 10.2967/jnumed.109.070714.


Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Saï-Maurel C, Campion L, Faivre-Chauvet A, Mirallié E, Chérel M, Supiot S, Barbet J, Chatal JF, Thédrez P.

Mol Cancer Ther. 2002 Feb;1(4):267-74.


Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P.

J Nucl Med. 1999 Jan;40(1):198-204.


Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.

Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3183s-3189s.


Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.

Salaun PY, Bodet-Milin C, Frampas E, Oudoux A, Saï-Maurel C, Faivre-Chauvet A, Barbet J, Paris F, Kraeber-Bodéré F.

Cancer. 2010 Feb 15;116(4 Suppl):1053-8. doi: 10.1002/cncr.24792.


Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.

Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W.

Cancer Res. 1997 Dec 1;57(23):5309-19.


Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.

Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Fiche M, Gautherot E, Barbet J, Chatal JF.

J Nucl Med. 1998 Sep;39(9):1608-13.


Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.

Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL.

Thyroid. 2002 Nov;12(11):953-61.


Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts.

Kinuya S, Kawashima A, Yokoyama K, Koshida K, Konishi S, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N.

J Nucl Med. 2002 Aug;43(8):1084-9.


Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s.


Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy.

Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, Watanabe N, Shuke N, Bai J, Michigishi T, Tonami N.

Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):981-5. Epub 2004 Feb 28.


A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.

Clin Cancer Res. 2000 Oct;6(10):3855-63.


Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.

Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH.

Cancer Res. 2001 Jun 15;61(12):4716-22.


Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.

J Nucl Med. 2006 Jul;47(7):1127-35.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk